Abstracts tagged "Patient reported outcomes"

Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 0725 • ACR Convergence 2025
Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis
Rennie Rhee¹, Christine Yeung², Darrin White³, Mary Gibson³, Jessica Nguyen⁴, Cristina Burroughs⁵, Jennifer Gordon⁶, Noam A. Cohen⁴, Jeffrey Morris⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Vasculitis Patient-Powered Research Network, Philadelphia, PA, ³². Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of South Florida, Tampa, FL, ⁶Vasculitis Foundation, Kansas City, MO
Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…
Abstract Number: 0377 • ACR Convergence 2025
New efforts to incorporate patient-reported outcomes into clinical trials for lupus therapeutics
Patti Katz¹, Anca Askanase², Nandan Baruah³, Wen-Hung Chen⁴, Nicole Cooper⁵, Anna Fisch³, Lili Garrard⁶, Meenakshi Jolly⁷, Veronica Vargas Lupo⁸, Carla Menezes⁹, Judith Mills³, Hoang Nguyen¹⁰, Teodora Staeva⁵, Josephine Park¹¹ and Zahi Touma¹², ¹UCSF, San Rafael, CA, ²Columbia University Medical Center, New York, NY, ³Lupus Voices Council, Lupus Accelerating Breakthroughs Consortium, New York, ⁴GlaxoSmithKline, Philadelphia, PA, ⁵Lupus Research Alliance, New York, ⁶FDA, CDER, SIlver Spring, MD, ⁷Rush University, Chicago, ⁸Lupus Voices Council, Lupus Research Alliance, New York, NY, ⁹Lupus Therapeutics, New York, NY, ¹⁰Lupus Research Alliance, New York, NY, ¹¹EMDSerono, Boston, MA, ¹²University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Accelerating Breakthroughs Consortium (Lupus ABC) was formed by the Lupus Research Alliance as a public private partnership of people living with lupus, investigators,…
Abstract Number: 2508 • ACR Convergence 2025
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
Colebrooke Johnson¹, Nora Shepherd², David O'Dea¹, Andrew King², Guy Katz¹, Belen Arevalo Molina¹, Zachary Williams³, Madison Negron⁴, Naomi Patel¹ and Sebastian H Unizony⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Nancy, KY, ⁴Harvard Extension School, Medford, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) imposes a high morbidity burden, both from the disease itself and from treatment-related side effects, often compromising patients’ quality of life…
Abstract Number: 2065 • ACR Convergence 2025
Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
Lekshmi Minikumari Rahulan¹, Shounak Ghosh², Manali Sarkar³, Didem Saygin⁴, Karin Lodin⁵, Rima Shrestha⁶, Tulika Chatterjee⁷, Jessica Day⁸, Samuel Shinjo⁹, Sreoshy Saha¹⁰, Lorenzo Cavagna¹¹, Masataka Kuwana¹², Vikas Agarwal¹³ and Latika Gupta¹⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ²Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK, Wolverhampton, United Kingdom, ³Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁴Rush University Medical Center, Chicago, IL, ⁵Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Department of Research Services, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁷Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁸Walter and Eliza Hall Institute, Melbourne, Victoria, Australia, ⁹Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁰Mymensingh Medical College, Mymensingh, Bangladesh, Mymensingh, Bangladesh, ¹¹Associate Professor in Rheumatology (Internal Medicine and Thepaeutics),University of Pavia, Pavia, Lombardy, Italy, Physician in Chief of Myositis Outpatients Clinic,Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia,Italy, Lombardia, Italy, ¹²Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁴School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Pain remains a significant yet understudied aspect of idiopathic inflammatory myopathies (IIMs), considerably reducing quality of life despite advancements in immunomodulatory therapies. Information obtained…
Abstract Number: 1449 • ACR Convergence 2025
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Lianne S. Gensler¹, Sofia Ramiro², Denis Poddubnyy³, Marina Magrey⁴, Irene E. van der Horst-Bruinsma⁵, Atul Deodhar⁶, Vanessa Taieb⁷, Diana Voiniciuc⁸, Natasha de Peyrecave⁹ and Martin Rudwaleit¹⁰, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Leiden University Medical Center, Bunde, Netherlands, ³Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁴Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷UCB, Colombes, France, ⁸UCB, Slough, United Kingdom, ⁹UCB, Brussels, Belgium, ¹⁰Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown sustained efficacy to Week (Wk) 52…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…
Abstract Number: 0535 • ACR Convergence 2025
Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Chamaida Plasencia-Rodríguez⁴, Alejandro Balsa⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, MADRID, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Inflammatory back pain (IBP) is very relevant for identifying patients at risk of axial spondyloarthritis (axSpA). Mounting evidence has indicated substantial variability in sensitivity…
Abstract Number: 0371 • ACR Convergence 2025
Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
Judy Zhang¹, Leonard Calabrese², Shilpa Venkatachalam³, angela Degrassi⁴, Yuxuan Jin² and M. Elaine Husni⁵, ¹Cleveland Clinic, Cleveland, United States, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: As healthcare shifts towards patient-centered care, multifactorial lifestyle interventions, though effective, often impose time and resource burdens on patients. An online program like IMMUNE…
Abstract Number: 2455 • ACR Convergence 2025
Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Justin Arnold¹, Linda Ehrlich-Jones², Dominique Kinnett-Hopkins³, Linda Van Horn⁴, Grace Whiteford⁴, Lutfiyya muhammad⁵, Jing Song⁶, Joan Chmiel⁷, Rowland Chang⁵, Pamela Semanik⁷, Anh Chung⁸, Daniel Erickson⁴, Christie Bartels⁹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Shirley Ryan AbilityLab, Aurora, IL, ³University of Michigan, Ypsilanti, MI, ⁴Feinberg School of Medicine, Chicago, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Chicago, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with persistent fatigue. Physical activity (PA) & dietary intake are potential modifiable behaviors that can reduce fatigue in…
Abstract Number: 2063 • ACR Convergence 2025
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Julie Paik¹, Andrea Young², Zuzana Bologna³, Will Kelly³, Chris Mecoli⁴, Jemima Albayda² and Lisa Christopher-Stine², ¹Johns Hopkins Rheumatology, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a chronic inflammatory myopathy characterized by muscle weakness and skin rashes, yet its full impact on patient-reported outcomes remains under-explored. We…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1251 • ACR Convergence 2025
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
Michelle Petri¹, Martha Stone², John Stone³, meredith Marinaro⁴, Matt Wilkinson⁵, Walter Lentfert⁶, Camille Kotton⁷, Jeffrey Gelfand⁸, Jane McDowell⁹ and Tricha Shivas¹⁰, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Steritas, LLC, Concord, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Novartis, Hartford, CT, ⁵UpThereEverywhere, London, United Kingdom, ⁶UpThereEverywhere, Charlotte, NC, ⁷Harvard Medical School, Boston, MA, ⁸UCSF Department of Neurology, Mill Valley, CA, ⁹Queens University Belfast, Belfast, United Kingdom, ¹⁰Foundation for Sarcoidosis Research, Chicago, IL
Background/Purpose: We report on two years of engagement with Sam, a patient-facing program to optimize the use of glucocorticoids and discontinue them when possible. We…
Abstract Number: 0523 • ACR Convergence 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Jennifer Soung¹, Virginie Kelly², Marni Wiseman³, Adrian Rodriguez⁴, Theodore Alkousakis⁵, Olivia Choi⁵, Daphne Chan⁵, Katelyn Rowland⁵, Linda Hou⁶, Jenny Jeyarajah⁷, Nastaran Abbarin⁸, Elizabeth Skobelev⁵, Sancharitha Ramji⁵, James Krell⁹, Max Sauder¹⁰ and David Adam¹¹, ¹Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ²Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, ³SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, ⁴Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, ⁸Janssen Inc, Toronto, ON, Canada, Toronto, Canada, ⁹Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, ¹⁰Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, ¹¹CCA Medical Research, ON, Canada, Toronto, Canada
Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as…
Abstract Number: 0372 • ACR Convergence 2025
Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
Maria Romero Noboa¹, Hannah Howell², Angelo Gaffo³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].